{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-26-000019","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2026-08-28T20:06:46+00:00","discovered_at":"2026-08-28T20:08:03.231135+00:00","generated_at":"2026-08-28T20:08:10.341419+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PTC Therapeutics to acquire ST-920 gene therapy for Fabry disease from Sangamo for $111M upfront","bullets":["Upfront $111M plus up to $100M milestones: $80M on FDA accelerated approval, $20M on full approval of ST-920 BLA.","ST-920 is a one-time AAV gene therapy candidate for Fabry disease, acquired from Sangamo in bankruptcy auction.","Closing subject to Bankruptcy Court approval (hearing Sept 10, 2026) and HSR waiting period; deadline Oct 15, 2026.","PTC was selected as winning bidder in Sangamo's Chapter 11 case; agreement includes customary reps/warranties, no indemnification."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-26-000019","json":"https://secwatch.observer/filing/0001070081-26-000019.json","markdown":"https://secwatch.observer/filing/0001070081-26-000019.md","text":"https://secwatch.observer/filing/0001070081-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/0001070081-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/tmb-20260825x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-28T20:08:10.341419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}